Innoviva (INVA)
(Real Time Quote from BATS)
$16.20 USD
+0.01 (0.06%)
Updated May 14, 2024 10:54 AM ET
NA Value
NA Growth NA Momentum NA VGMIndustry / Sector Report
Industry : Large Cap Pharmaceuticals
Zacks Industry Rank
Bottom 39% (153 out of 250)Zacks Sector Rank
Top 31% (5 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 3.00 | 2.10 | 9.99 |
Current Quarter Estimate | NA | 37.64 | 57.00 |
Year Ago Quarter Estimate | NA | 11.39 | 52.54 |
Next Quarter Estimate | NA | 34.85 | 61.00 |
Next Year Estimate | NA | 178.47 | 270.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | NA | NA | NA |
Next Year | NA | NA | NA |
Last 5 Years | NA | NA | NA |
Next 5 Years | NA | NA | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | 7.10 | 15.53 |
Price/Book (MRQ) | 1.45 | 5.76 |
Price/Cash Flow (MRFY) | 4.63 | 10.06 |
Dividend Yield | 0.00% | 2.44% |
Net Profit Margin (TTM) | 58.21% | 15.19% |
Return on Equity (TTM) | 28.94% | 31.29% |
Debt to Equity (MRQ) | 0.63 | 39.85 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.